Quantum-Si Incorporated — Cyborg Score 4/10

Strategic Profile

Quantum-Si targets the expanding proteomics market by replacing traditional, multistep mass spectrometry workflows with direct single-molecule protein sequencing. The company leverages proprietary semiconductor chip technology based on time-domain sequencing to position itself as a high-resolution alternative in antibody characterization, biomarker identification, and protein variant analysis.

Cyborg Score Rationale

Quantum-Si shows promising technology and expanding revenue (182% YoY growth in 2024), but operates at significant losses (-$101M in 2024) with early market adoption. Stock performance has lagged broader biotech indices, indicating investor concerns about path to profitability despite strong technical catalysts.

Top Insights

• Revenue surged 182% to $3.06M in 2024, though from a modest base, indicating early market traction
• Operating losses remain substantial at -$101M annually, highlighting pre-profitability stage despite growth
• Prototype Proteus platform showed successful sequencing capability in Q3 2025, signaling next-generation product pipeline maturation
• Raised $50M via registered direct offering in late 2025, providing runway for commercialization and product development

Named Competitors

• DNA Sequencing Platforms — Long-read DNA sequencing technology
• Proteomics/Mass Spectrometry — Traditional multistep protein analysis workflows

Recent Developments

• November 2025: Announced successful sequencing on Proteus platform prototype; Investor & Analyst Day highlighted technology pipeline progress
• August 2025: Q2 2025 earnings reported showing continued revenue growth momentum
• Q4 2025: Earnings call scheduled for March 3, 2026 (today)

Open the full interactive Quantum-Si Incorporated report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.